Immunohistochemistry as a reliable predictor of remission in patients with endometrial cancer: Establishment and validation of a machine learning model

Wang,Ruiqi; Wang,Jingyuan; Wu,Yuman; Zhu,Aoxuan; Li,Xingchen; Wang,Jianliu

doi:10.3892/ol.2024.14805

Immunohistochemistry as a reliable predictor of remission in patients with endometrial cancer: Establishment and validation of a machine learning model

Authors:
- Ruiqi Wang
- Jingyuan Wang
- Yuman Wu
- Aoxuan Zhu
- Xingchen Li
- Jianliu Wang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, P.R. China
Published online on: November 15, 2024 https://doi.org/10.3892/ol.2024.14805
Article Number: 59
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endometrial cancer (EC) is the most common gynecologic cancer. Unfortunately, its prognosis remains poor due to limited screening and treatment options. To address this issue, the present study evaluated the predictive value of four immunohistochemical (IHC) indicators for overall survival (OS) and recurrence‑free survival (RFS) in patients with EC. A total of 834 patients diagnosed with EC were included at Peking University People's Hospital between January 2006 and December 2020. These patients were randomly divided into training and validation cohorts at a 2:1 ratio, collecting data on clinicopathological information and IHC indicators. A total of 92 combinations of algorithms were assessed using the Leave‑One‑Out Cross‑Validation framework to identify the one with the highest C‑index. To estimate the accuracy of the factors and four IHC indicators for predicting both OS and RFS, survival curves and receiver operating characteristic (ROC) curves were used. Independent predictors included estrogen receptor, progesterone receptor, body mass index, P53, FIGO stage, histology, grade, Ki67, ascites and lymph node metastasis. Both the training and validation cohorts exhibited excellent predictive performance for OS and RFS, as demonstrated by ROC curves at 1‑year, 3‑year and 5‑year follow‑ups. By introducing a model based solely on clinicopathological information as model 1 and adding four IHC indicators in model 2, a significant improvement was observed in the area under the curve (AUC) values across the entire sample. The AUC value for OS curves increased from 0.765 to 0.872, and the AUC for RFS curves rose from 0.791 to 0.882. Thus, the present study's model effectively predicts patients' probability of OS and RFS using these factors. This prediction capability can guide postoperative treatment plans and follow‑up intervals, potentially enhancing long‑term survival for patients with EC.

View Figures

View References

1	Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D and Oaknin A: Endometrial cancer. Nat Rev Dis Primers. 7:882021. View Article : Google Scholar : PubMed/NCBI
2	Medina HN, Penedo FJ, Joachim C, Deloumeaux J, Koru-Sengul T, Macni J, Bhakkan B, Peruvien J, Schlumbrecht MP and Pinheiro PS: Endometrial cancer risk and trends among distinct African descent populations. Cancer. 129:2717–2726. 2023. View Article : Google Scholar : PubMed/NCBI
3	Piechocki M, Koziołek W, Sroka D, Matrejek A, Miziołek P, Saiuk N, Sledzik M, Jaworska A, Bereza K, Pluta E and Banas T: Trends in incidence and mortality of gynecological and breast cancers in Poland (1980–2018). Clin Epidemiol. 14:95–114. 2022. View Article : Google Scholar : PubMed/NCBI
4	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
5	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
6	Mitric C and Bernardini MQ: Endometrial cancer: Transitioning from histology to genomics. Curr Oncol. 29:741–757. 2022. View Article : Google Scholar : PubMed/NCBI
7	Cancer Genome Atlas Research Network, . Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, et al: Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI
8	Bruno V, Betti M, D'Ambrosio L, Massacci A, Chiofalo B, Pietropolli A, Piaggio G, Ciliberto G, Nisticò P, Pallocca M, et al: Machine learning endometrial cancer risk prediction model: Integrating guidelines of European society for medical oncology with the tumor immune framework. Int J Gynecol Cancer. 33:1708–1714. 2023. View Article : Google Scholar : PubMed/NCBI
9	Perrone E, De Felice F, Capasso I, Distefano E, Lorusso D, Nero C, Arciuolo D, Zannoni GF, Scambia G and Fanfani F: The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method. Gynecol Oncol. 165:585–593. 2022. View Article : Google Scholar : PubMed/NCBI
10	Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK, Method M, Ade M, Ivanova A and Boggess F: A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): A multicentre, prospective, cohort study. Lancet Oncol. 18:384–392. 2017. View Article : Google Scholar : PubMed/NCBI
11	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
12	Njoku K, Barr CE and Crosbie EJ: Current and emerging prognostic biomarkers in endometrial cancer. Front Oncol. 12:8909082022. View Article : Google Scholar : PubMed/NCBI
13	Coll-de la Rubia E, Martinez-Garcia E, Dittmar G, Gil-Moreno A, Cabrera S and Colas E: Prognostic biomarkers in endometrial cancer: A systematic review and meta-analysis. J Clin Med. 9:19002020. View Article : Google Scholar : PubMed/NCBI
14	Vrede SW, van Weelden WJ, Visser NCM, Bulten J, van der Putten LJM, van de Vijver K, Santacana M, Colas E, Gil-Moreno A, Moiola CP, et al: Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. Gynecol Oncol. 161:787–794. 2021. View Article : Google Scholar : PubMed/NCBI
15	Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, et al: Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 123:802–813. 2017. View Article : Google Scholar : PubMed/NCBI
16	Singh N, Piskorz AM, Bosse T, Jimenez-Linan M, Rous B, Brenton JD, Gilks CB and Köbel M: p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J Pathol. 250:336–345. 2020. View Article : Google Scholar : PubMed/NCBI
17	Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, et al: TP53 sequencing and p53 immunohistochemistry predict outcomes when bevacizumab is added to frontline chemotherapy in endometrial cancer: An NRG Oncology/Gynecologic oncology group study. J Clin Oncol. 40:3289–3300. 2022. View Article : Google Scholar : PubMed/NCBI
18	Perrone E, Capasso I, De Felice F, Giannarelli D, Dinoi G, Petrecca A, Palmieri L, Foresta A, Nero C, Arciuolo D, et al: Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification. Eur J Cancer. 186:98–112. 2023. View Article : Google Scholar : PubMed/NCBI
19	Guan J, Xie L, Luo X, Yang B, Zhang H, Zhu Q and Chen X: The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: Hormone receptors in risk stratification. J Gynecol Oncol. 30:e132019. View Article : Google Scholar : PubMed/NCBI
20	Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S and Auranen A: Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecol Oncol. 130:463–469. 2013. View Article : Google Scholar : PubMed/NCBI
21	Jia M, Pi J, Zou J, Feng M, Chen H, Lin C, Yang S and Xiao X: The potential value of ki-67 in prognostic classification in early low-risk endometrial cancer. Cancer Control. 30:107327482312069292023. View Article : Google Scholar : PubMed/NCBI
22	Wang Z, Zhang S, Ma Y, Li W, Tian J and Liu T: A nomogram prediction model for lymph node metastasis in endometrial cancer patients. BMC Cancer. 21:7482021. View Article : Google Scholar : PubMed/NCBI
23	Feng X, Li XC, Yang X, Cheng Y, Dong YY, Wang JY, Zhou JY and Wang JL: Metabolic syndrome score as an indicator in a predictive nomogram for lymph node metastasis in endometrial cancer. BMC Cancer. 23:6222023. View Article : Google Scholar : PubMed/NCBI
24	Yang XL, Huang H, Kou LN, Lai H, Chen XP and Wu DJ: Construction and validation of a prognostic model for stage IIIC endometrial cancer patients after surgery. Eur J Surg Oncol. 48:1173–1180. 2022. View Article : Google Scholar : PubMed/NCBI
25	van der Putten LJM, Visser NCM, van de Vijver K, Santacana M, Bronsert P, Bulten J, Hirschfeld M, Colas E, Gil-Moreno A, Garcia A, et al: Added value of estrogen receptor, progesterone receptor, and L1 cell adhesion molecule expression to histology-based endometrial carcinoma recurrence prediction models: An ENITEC collaboration study. Int J Gynecol Cancer. 28:514–523. 2018. View Article : Google Scholar : PubMed/NCBI
26	Liu L, Yuan S, Yao S, Cao W and Wang L: EPPK1 as a prognostic biomarker in type I endometrial cancer and its correlation with immune infiltration. Int J Gen Med. 17:1677–1694. 2024. View Article : Google Scholar : PubMed/NCBI
27	Chen J, Yang P, Li S and Feng Y: Increased FOXM1 expression was associated with the prognosis and the recruitment of neutrophils in endometrial cancer. J Immunol Res. 2023:54375262023. View Article : Google Scholar : PubMed/NCBI
28	Ma H, Feng PH, Yu SN, Lu ZH, Yu Q and Chen J: Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma. BMC Cancer. 22:5432022. View Article : Google Scholar : PubMed/NCBI
29	Piedimonte S, Feigenberg T, Drysdale E, Kwon J, Gotlieb WH, Cormier B, Plante M, Lau S, Helpman L, Renaud MC, et al: Predicting recurrence and recurrence-free survival in high-grade endometrial cancer using machine learning. J Surg Oncol. 126:1096–1103. 2022. View Article : Google Scholar : PubMed/NCBI
30	Feng Y, Wang Z, Xiao M, Li J, Su Y, Delvoux B, Zhang Z, Dekker A, Xanthoulea S, Zhang Z, et al: An applicable machine learning model based on preoperative examinations predicts histology, stage, and grade for endometrial cancer. Front Oncol. 12:9045972022. View Article : Google Scholar : PubMed/NCBI